Intended Audience: Psychiatrists, nurse practitioners, physician assistants, nurses, pharmacists, case managers, and psychologists working in psychiatry specialty settings

Transitioning from inpatient to outpatient care is a time of great stress and vulnerability for patients with schizophrenia. All too often, patients fail to follow-up with their outpatient care team or remain adherent with their established medical management and antipsychotic medications which can lead to relapses, rehospitalizations, and decreased quality of life.

Download this schizophrenia transitions of care pathway tool to learn the latest information and strategies to manage schizophrenia care across the inpatient-outpatient spectrum and advance patient-centered schizophrenia care.

This Transitions of Care Pathway is delivered in partnership with NTOCC and the CureSZ Foundation.

This activity is part of a series, learners seeking American Psychological Association (APA) credit must complete all activities in this Learning Lab.

• Identify and address gaps in schizophrenia care that occur as patients transition between inpatient and outpatient care, leading to poor adherence and relapse
• Engage patients and their caregivers in shared decision-making to guide individualized treatment plans that address clinical needs, side effects, long-term goals, and preferences
• Incorporate interprofessional strategies to support communication and care coordination among schizophrenia care teams to improve long-term outcomes

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• John M. Kane, M.D (Contributing Author)
  
  Advisory Board or Panel – Cerevel, Click Therapeutics, Dainippon Sumitomo, H. Lundbeck, Merck, Newron, Novartis, Otsuka, Teva Pharmaceuticals
  Consultant – Alkermes, Allergan, Boehringer Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HLS, HealthRhythms, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, LB Pharmaceuticals, Merck, Minerva, NW Pharma Tech, Neurocrine, Newron, Novartis, Otsuka, Roche, Saladax, Sunovion, Teva Pharmaceuticals
  Grants / Research Support – H. Lundbeck, Janssen Pharmaceutical, Otsuka, Sunovion, Teva Pharmaceuticals
  Stock / Shareholder (self- managed) – LB Pharmaceuticals, MedinCell, NW Pharma Tech, North Shore Therapeutics, Vanguard Research Group
  Other Financial or Material Support (royalties, patents, etc.) – UpToDate
  The relationships reported above are related to the following therapeutic area: Psychiatry
• Cheri Lattimer, RN, BSN (Contributing Author)
  
  Advisory Board or Panel – Ferring Pharmaceutical
  The relationships reported above are related to the following therapeutic area: Gastroenterology
• Bethany Yeiser (Contributing Author)
  
  Advisory Board or Panel – Alkermes
  Grants / Research Support – Janssen, Karuna Therapeutics, Neurocrine Biosciences
  Speakers Bureau or other Promotional Education – Psych Congress (HMP Global)
  Other Financial or Material Support (royalties, patents, etc.) – Neurocrine Biosciences
  The relationships reported above are related to the following therapeutic area: Psychiatry
• Jose M Rubio, MD (Contributing Author)
  
  Advisory Board or Panel – Janssen, Karuna, Teva Pharmaceuticals
  Consultant – Medscape
  Grants / Research Support – Alkermes
  Speakers Bureau or other Promotional Education – Teva Pharmaceuticals
  Other Financial or Material Support (royalties, patents, etc.) – UpToDate
  The relationships reported above are related to the following therapeutic area: Psychiatry

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• M David Rudd, PhD, ABPP (Reviewer)
• Abimbola Farinde, PhD, PharmD (Planner)
• Joyce M Knestrick, PhD, CRNP, FAANP (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.